Last reviewed · How we verify

NCT05701345

Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder

Completed NA Last updated 4 November 2024
What this trial tests

NA trial testing OMNIFIT DTx-MDD in Depressive Disorder in 162 participants. Completed in 1 November 2024.

Timeline
9 March 2023
Primary endpoint
1 November 2024
1 November 2024

Quick facts

Lead sponsorOmni C&S
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment162
Start date9 March 2023
Primary completion1 November 2024
Estimated completion1 November 2024
Sites5 locations across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Omni C&S

Who can join

Adults 19 to 64, any sex, with Depressive Disorder or Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks. The investigator would like to confirm evaluate the safety and efficacy of the wearable visual device(HMD)-VR-based software medical device effect of improving depressive disorder in patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Depressive Disorder

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05701345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing